Prothena Corp (PRTA)

$7.87 +0.84 (11.95%)
Market Cap 373.56M
Revenue (ttm) 135.16M
Net Income (ttm) -122.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.49%
Debt to Equity Ratio 0.00
Volume 2,455,364
Avg Vol 1,688,190
Day's Range N/A - N/A
Shares Out 53.83M
Stochastic %K 49%
Beta -0.03
Analysts Sell
Price Target $24.29

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antib...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 236 2500
Fax: 353 1 902 3510
Address:
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 7:12 PM
$PRTA Short sellers were driving this down into the ground. Even with today’s P3 news from Novo Nordisk, the MC is about $370M which is the net cash level. The Novo deal is for PRTA to receive $1.2B upon successful P3. That is only from the announced P3 drug for Amyloid. The real potential is the AD vaccine and PD drug that will also be in P3 with Roche. The short sellers were betting on $0. What a stupid bunch. LMAO
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 6 at 5:29 PM
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful $PRTA $NVO https://stocktwits.com/news/equity/markets/novo-nordisk-commits-to-advancing-prothena-corp-developed-drug-into-late-stage-trial/chrSdM5Rd5l
0 · Reply
stocks271
stocks271 Aug. 6 at 3:04 PM
$PRTA looking good. Ripe for squeeze
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 3:04 PM
$PRTA If the AD vaccine data show potentially good efficacy, this will be the meme stock of all history of mankind. LOL JMO 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 2:37 PM
$PRTA 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
0 · Reply
MonkeyMan24
MonkeyMan24 Aug. 6 at 2:31 PM
$PRTA
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 1:47 PM
$PRTA LFG!!!!!! 🚀🔥🚀🔥🚀🔥🚀🔥
0 · Reply
anachartanalyst
anachartanalyst Aug. 5 at 3:02 PM
$PRTA https://anachart.com/wp-content/uploads/ana_temp/1754406123_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 12:30 PM
HC Wainwright & Co. has adjusted their stance on Prothena Corp ( $PRTA ), setting the rating to Buy with a target price of 14.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 5 at 10:53 AM
WATCHLIST AUG 05 2025. $CVKD Cadrenal Therapeutics Announced Trial Initiation Plans For Tecarfarin For End-stage Kidney Disease Patients Who Are Transitioning To Dialysis. Enrollment Is Planned To Begin Later This Year And Will Include Patients With And Without Atrial Fibrillation $DD DuPont De Nemours On Track For Nov. 1 Spinoff Date For Electronics Business Creating New Independent, Publicly Traded Electronics Company "Qnity Electronics, Inc." $ATKR Atkore CEO Bill Waltz Announces Retirement Plans; Board Of Directors Begins Search For New Chief Executive $PRTA Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target $PRAA PRA Group shares are trading higher after the company reported a year-over-year increase in Q2 GAAP EPS results and better-than-expected Q2 sales results.
0 · Reply
Latest News on PRTA
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 6, 2025, 9:00 AM EDT - 6 hours ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 4, 2025, 4:05 PM EDT - 1 day ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jul 28, 2025, 4:05 PM EDT - 8 days ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Announces Corporate Restructuring

Jun 18, 2025, 4:05 PM EDT - 6 weeks ago

Prothena Announces Corporate Restructuring

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Jun 16, 2025, 1:06 AM EDT - 7 weeks ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Why Is Prothena Stock Trading Lower On Tuesday?

May 27, 2025, 7:43 AM EDT - 2 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025, 4:05 PM EDT - 2 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 9, 2025, 7:16 AM EDT - 3 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 3 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

May 1, 2025, 4:05 PM EDT - 3 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 8:45 PM EST - 5 months ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 20, 2025, 4:05 PM EST - 5 months ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 17, 2025, 6:10 PM EST - 6 months ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Feb 13, 2025, 4:05 PM EST - 6 months ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Prothena Announces Board of Directors Update

Dec 30, 2024, 4:05 PM EST - 7 months ago

Prothena Announces Board of Directors Update

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Dec 19, 2024, 1:05 AM EST - 8 months ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 9 months ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena to Report Third Quarter 2024 Financial Results on November 12

Nov 5, 2024, 4:05 PM EST - 9 months ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Announces Leadership Team Updates

Sep 27, 2024, 4:05 PM EDT - 11 months ago

Prothena Announces Leadership Team Updates

Prothena to Participate in Upcoming Healthcare Conferences

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Report Second Quarter 2024 Financial Results on August 8

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena to Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Mar 4, 2024, 4:05 PM EST - 1 year ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23, 2024, 12:31 PM EST - 1 year ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 21, 2024, 4:05 PM EST - 1 year ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 11:53 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Feb 8, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Jan 8, 2024, 8:30 AM EST - 1 year ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena prepares for potential sale - Bloomberg News

Oct 16, 2023, 11:57 AM EDT - 1 year ago

Prothena prepares for potential sale - Bloomberg News

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Sep 21, 2023, 1:39 PM EDT - 2 years ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 27, 2023, 7:23 AM EDT - 2 years ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Jul 10, 2023, 4:10 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Jun 27, 2023, 4:05 PM EDT - 2 years ago

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Prothena to Participate in Jefferies 2023 Healthcare Conference

Jun 2, 2023, 4:05 PM EDT - 2 years ago

Prothena to Participate in Jefferies 2023 Healthcare Conference

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

May 16, 2023, 4:05 PM EDT - 2 years ago

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

May 7, 2023, 2:28 AM EDT - 2 years ago

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

May 4, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Prothena to Report First Quarter 2023 Financial Results on May 4

Apr 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena to Participate in 2023 Bank of America Healthcare Conference

Apr 24, 2023, 4:05 PM EDT - 2 years ago

Prothena to Participate in 2023 Bank of America Healthcare Conference

AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 7:12 PM
$PRTA Short sellers were driving this down into the ground. Even with today’s P3 news from Novo Nordisk, the MC is about $370M which is the net cash level. The Novo deal is for PRTA to receive $1.2B upon successful P3. That is only from the announced P3 drug for Amyloid. The real potential is the AD vaccine and PD drug that will also be in P3 with Roche. The short sellers were betting on $0. What a stupid bunch. LMAO
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 6 at 5:29 PM
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful $PRTA $NVO https://stocktwits.com/news/equity/markets/novo-nordisk-commits-to-advancing-prothena-corp-developed-drug-into-late-stage-trial/chrSdM5Rd5l
0 · Reply
stocks271
stocks271 Aug. 6 at 3:04 PM
$PRTA looking good. Ripe for squeeze
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 3:04 PM
$PRTA If the AD vaccine data show potentially good efficacy, this will be the meme stock of all history of mankind. LOL JMO 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 2:37 PM
$PRTA 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
0 · Reply
MonkeyMan24
MonkeyMan24 Aug. 6 at 2:31 PM
$PRTA
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 6 at 1:47 PM
$PRTA LFG!!!!!! 🚀🔥🚀🔥🚀🔥🚀🔥
0 · Reply
anachartanalyst
anachartanalyst Aug. 5 at 3:02 PM
$PRTA https://anachart.com/wp-content/uploads/ana_temp/1754406123_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 12:30 PM
HC Wainwright & Co. has adjusted their stance on Prothena Corp ( $PRTA ), setting the rating to Buy with a target price of 14.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 5 at 10:53 AM
WATCHLIST AUG 05 2025. $CVKD Cadrenal Therapeutics Announced Trial Initiation Plans For Tecarfarin For End-stage Kidney Disease Patients Who Are Transitioning To Dialysis. Enrollment Is Planned To Begin Later This Year And Will Include Patients With And Without Atrial Fibrillation $DD DuPont De Nemours On Track For Nov. 1 Spinoff Date For Electronics Business Creating New Independent, Publicly Traded Electronics Company "Qnity Electronics, Inc." $ATKR Atkore CEO Bill Waltz Announces Retirement Plans; Board Of Directors Begins Search For New Chief Executive $PRTA Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target $PRAA PRA Group shares are trading higher after the company reported a year-over-year increase in Q2 GAAP EPS results and better-than-expected Q2 sales results.
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 10:30 AM
Chardan Capital has updated their rating for Prothena Corp ( $PRTA ) to Buy with a price target of 18.
0 · Reply
Newtimmy
Newtimmy Aug. 4 at 8:44 PM
$PRTA
0 · Reply
QuantInsider
QuantInsider Jul. 31 at 3:45 PM
What's up with $PRTA? Two massive 150-contract put blocks at the $7.5 strike for Aug 15 just popped up on InsiderFinance Each went for $12K, suggesting some folks are hedging their bets with downside protection This clashes with the strong Phase 2 data we’ve seen The near-term direction looks a bit murky Might be wise to hold back on new long positions until things clear up a bit
2 · Reply
AIIAAIIA_88
AIIAAIIA_88 Jul. 31 at 12:14 AM
$PRTA Just getting started.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Jul. 29 at 1:54 PM
$PRTA This damn thing is trading below the net cash value of $7.5, meaning all the failure of its pipeline (AD + PD) is priced in. Sure, it will keep spending on clinical trials and will go to zero if nothing succeeds. But if just one thing works out, either for AD or PD, this stock is off the chart. I say that it is a good risk/reward ratio. LOL JMO
2 · Reply
JarvisFlow
JarvisFlow Jul. 29 at 11:00 AM
Oppenheimer has adjusted their stance on Prothena Corp ( $PRTA ), setting the rating to Outperform with a target price of 62 → 58.
0 · Reply
MonkeyMan24
MonkeyMan24 Jul. 28 at 8:52 PM
$PRTA bought a bunch of December $20 calls. Roast me
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Jul. 25 at 6:55 PM
$PRTA Parkinson’s in P3 with Roche and Alzheimer’s vaccine data coming up! This stock can make all other meme stocks look like a child’s play! JMO
1 · Reply
janon10
janon10 Jul. 23 at 2:53 PM
$PRTA well rotation to healthcare iniciated, and this one was one of my kind. Added.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Jul. 23 at 3:17 AM
$PRTA Just go to $80 within this year please. Would that be too much? Thanks.
1 · Reply
Newtimmy
Newtimmy Jul. 20 at 7:37 PM
$PRTA Contemplating a position in here. What is the prevailing bull and/or bear case
1 · Reply
buyandsold
buyandsold Jul. 16 at 7:08 PM
$PRTA 1/3 of my port in this.
1 · Reply